Navigation Links
Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel
Date:2/11/2009

mcy, M.D., president and chief executive officer of Portola. "By combining their strengths with our own research and development expertise in thrombosis, we have a great opportunity to significantly improve the lives of millions of patients worldwide."

Elinogrel is the only direct acting, reversible, i.v. and oral P2Y12 ADP receptor antagonist in clinical development. Inhibiting the P2Y12 ADP receptor on platelets has been proven to prevent thrombosis and subsequent heart attacks. Because of its properties, elinogrel has the potential to provide significant clinical advantages compared to Plavix(R)* (clopidogrel), the current standard of care, and to newer agents in development, such as prasugrel, by lowering the risk of ischemic events due to clot formation and reducing the risk of bleeding. In addition, elinogrel is the only compound in development that can be administered intravenously in the hospital and orally in the chronic setting.

In Portola's clinical studies to date with the i.v. and oral formulations, results showed that elinogrel appeared to be well-tolerated without serious adverse events and demonstrated predictable, dose-dependent platelet inhibition. At the American Heart Association Scientific Sessions in November 2008, Dr. Paul Gurbel presented data that showed elinogrel overcomes high platelet reactivity, which is a known marker for adverse ischemic events in patients non-responsive to clopidogrel.

In December 2008, Portola initiated patient enrollment in INNOVATE-PCI, an 800-patient Phase 2 clinical trial of the i.v. and oral forms of elinogrel in a broad group of patients undergoing non-urgent percutaneous coronary intervention. Portola, together with Novartis, plans to further develop elinogrel to treat patients with acute coronary syndromes and broadly in patients with a prior heart attack or stroke, and those with peripheral vascular disease.

* Plavix(R) is
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... (PRWEB) November 24, 2014 Global ... 6.19 billion by 2020, according to a new ... rates of cardiac arrhythmias clubbed with growing global ... this market. Though still in the budding stage, ... rise in usage rates in the recent times, ...
(Date:11/24/2014)... 2014 Residents of retirement communities in ... year’s SENIORS GOT TALENT, an annual online talent competition ... players to classic crooners, to seniors partying on a ... are indeed living young. , “SENIORS GOT TALENT, while ... cash prize, has always been about highlighting the vibrancy ...
(Date:11/24/2014)... York (PRWEB) November 24, 2014 The ... by the Family and Children's Association to ... as soap, shampoo, mouthwash and other such items.The Association's ... who are home bound, living in nursing homes, assisted ... to greatly enhance the well being of seniors throughout ...
(Date:11/24/2014)... SafeHandles™ announced that they will be featured ... Jr, airing via Discovery Channel. Dates and show times ... non-invasive, replaceable, and affordable germ protective device. This segment ... and adhesives to promote hand hygiene in high traffic ... SafeHandles is the desire to make a positive impact ...
(Date:11/24/2014)... Pittsburgh, PA (PRWEB) November 24, 2014 ... as he was trying to cross the street in ... "The driver never saw him. I came up with ... easily visible at night." , He developed the Safety ... night or in low-lighting conditions. The device ensures that ...
Breaking Medicine News(10 mins):Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 2Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 3Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 4Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 2Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 3Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2
... the world will gather for Digestive Disease Week 2010 ... May 1 to May 5, 2010, at the Ernest ... the annual meeting of the American Gastroenterological Association (AGA) ... world. AGA researchers will present exciting, cutting-edge data during ...
... symptoms, could help speed diagnosis, findings show , FRIDAY, ... technique can identify changes in speech associated with the ... found. , "This is a noninvasive, reliable and accurate ... a few simple sentences," Shimon Sapir, of the department ...
... ... to child health advocacy , ... Vancouver, BC (Vocus) April 30, 2010 -- Pediatric experts from Children,s National ... 2010 Pediatric Academic Societies Annual Meeting—one of the largest annual meetings of health experts focused ...
... ... 18th during Hearing Aid Roundup , ... Braunfels, TX (Vocus) April 30, 2010 -- Estes Audiology and the Windcrest SERTOMA ... down to the Hearing Aid Roundup at Estes Audiology in New Braunfels on Tuesday, May 18, ...
... fares worse than many other countries, CDC experts say , ... latest year for which figures are available, about seven infants ... 3 percent drop from 2005 and the lowest infant death ... the drop in infant mortality was significant, the United States ...
... washes , FRIDAY, April 30 (HealthDay News) -- Rinsing the ... way to try to reduce allergy symptoms and sinus infections ... simple treatment might also help prevent ear infections in young ... received an average of four nasal irrigations four days a ...
Cached Medicine News:Health News:AGA presents cutting-edge research during DDW 2Health News:AGA presents cutting-edge research during DDW 3Health News:AGA presents cutting-edge research during DDW 4Health News:Voice Analysis May Allow Early Detection of Parkinson's 2Health News:Experts from Children's National Medical Center to present at Pediatric Academic Societies' Annual Meeting 2Health News:Experts from Children's National Medical Center to present at Pediatric Academic Societies' Annual Meeting 3Health News:Estes Audiology and SERTOMA Club Windcrest Celebrate Better Hearing and Speech Month with Hearing Aid Roundup 2Health News:Estes Audiology and SERTOMA Club Windcrest Celebrate Better Hearing and Speech Month with Hearing Aid Roundup 3Health News:U.S. Infant Deaths on the Decline 2Health News:U.S. Infant Deaths on the Decline 3Health News:Nasal Saline Rinses Reduce Ear Infections in Kids 2Health News:Nasal Saline Rinses Reduce Ear Infections in Kids 3
(Date:11/24/2014)... 2014  GlySens Incorporated announced today that it has ... the National Institute of Diabetes and Digestive and Kidney ... Health (NIH).  The grant is intended to support human ... term implantable glucose monitoring system.  Final preparations for launch ... to begin before the end of 2014. ...
(Date:11/23/2014)... Nov. 23, 2014 Anthera Pharmaceuticals, Inc. (Nasdaq: ... F. Truex , President and Chief Executive Officer, will ... Jaffray Healthcare Conference. Anthera will present ... Palace Hotel in New York City ... Anthera Pharmaceuticals is a biopharmaceutical company focused on developing ...
(Date:11/22/2014)... NEWTOWN, Pennsylvania , 21 de noviembre de ... servicios de ensayos clínicos externalizados y tecnologías eClinical, ... su aproximación de ,seguimiento inteligente, para el seguimiento ... El seguimiento inteligente amplía el concepto del seguimiento ... simple reducción de las visitas de seguimiento o ...
Breaking Medicine Technology:GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference 2El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3
... TSX: BMR, TORONTO, July 10, 2007 /PRNewswire-FirstCall/ ... to the,development and commercialization of cancer therapies, ... independent team in,Basel, Switzerland validates tenascin as ... new treatments for glioblastoma,multiforme (GBM). , The ...
... 2007 - BusinessWeek,published an article on July ... companies to be first to bring to,market ... angiogenesis therapies are being pursued by,Sanofi-Aventis, Boston ... highlights a very promising new biological,therapy for ...
Cached Medicine Technology:Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings 2Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings 3Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings 4BusinessWeek Article Highlights Promising Breakthrough Treatment,for Advanced Coronary Artery Disease 2
Easy to use practice management software....
... The Advia 120 ... to streamline laboratory workflow ... benefits. This analyzer offers ... diagnostic assays, meeting the ...
The SE-9500 automated hematology analyzerprovides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test results for enhanced screening ability....
The XE-2100L automated hematology analyzer features new hematology parameters as NRBC, IRF, and HPC that offer valuable and accurate clinical information....
Medicine Products: